Table 3.
Methamphetamine Use, Sexual Risk Behaviors, and Retention
| EMA+Dashboard N = 16 |
EMA+Dashboard+Counselor N = 18 |
Historical Matches N = 102 |
Comparison of the three treatment conditions Test statistic |
|||||
|---|---|---|---|---|---|---|---|---|
| Variable | Week 1 (n = 16) |
Week 12 (n = 13) |
Week 1 (n = 18) |
Week 12 (n = 12) |
Week 1 (n = 101) |
Week 12 (n = 76) |
Week 1 | Week 12 |
| Methamphetamine use and sexual risk behaviors, Median (IQR) | ||||||||
| Methamphetamine use (days in previous 30) | 5.0 (0.0-10.5) | 1.0 (0.0-6.0) | 11.5 (2.5-19.5) | 0.0 (0.0-2.0) | 5.5 (1.3-15.0) | 1.0 (0.0-6.3)a | KW χ2(2) = 2.0 | KW χ2(2) = 1.6 |
| Male sexual partners (# in previous 30 days) | 1.5 (0.0-4.3) | 0.5 (0.0-2.8) | 1.5 (1.0-5.5) | 0.0 (0.0-1.0) | 2.0 (1.0-6.0) | 1.0 (0.0-2.0) | KW χ2(2) = 1.6 | KW χ2(2) = 2.8 |
| Unprotected anal sex with non-primary partner (times in previous 30 days) | 0.0 (0.0-0.0) | 0.0 (0.0-0.0) | 2.0 (0.0-7.0) | 0.0 (0.0-0.0) | 1.0 (0.0-5.0) | 0.0 (0.0-1.0) | KW χ2(2) = 7.2 * | KW χ2(2) = 6.1 * |
| Urine drug screening for methamphetamine | ||||||||
| Joint probability index | ||||||||
| 8 weeks | 0.54 | 0.44 | 0.38 | |||||
| 12 weeks | 0.69 | 0.56 | 0.52 | |||||
| Treatment effectiveness score (Weeks 1-8), Median (IQR) | 17.0 (9.0-21.3) | 11.5 (8.0-19.5) | 11.0 (2.3-18.0) | KW χ2(2) = 2.8 | ||||
| Percentage of samples negative (Weeks 1-8), Median (IQR)b | 100.0 (80.9-100.0) | 90.5 (81.7-100.0) | 100.0 (78.3-100.0) | KW χ2(2) = 0.8 | ||||
| Longest consecutive negative samples (Weeks 1-8), Median (IQR)b | 8.5 (4.5-15.5) | 6.0 (4.0-10.0) | 5.0 (1.3-10.8) | KW χ2(2) = 3.8 | ||||
| Samples negative (Week 12), N (%)b | 11 (68.8) | 10 (55.6) | 53 (52.0) | χ2(2) = 1.6 | ||||
| Retention (final week), Median (IQR) | 5.5 (5.0-6.0) | 6.0 (5.0-6.0) | 6.0 (5.0-6.0) | KW χ2(2) = 0.1 | ||||
Note. IQR = interquartile range. KW = Kruskal-Wallis.
a
n = 64.
b
Missing urine samples were treated as samples tested positive for methamphetamine metabolites in the analysis.
*
p ≤ .05.